---
$id: https://graph.org.ai/products/commodity/51111780
$type: Product
source: UNSPSC
code: "51111780"
title: "Durvalumab"
class: "51111700"
classTitle: "Antineoplastic antibiotics"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Durvalumab

**UNSPSC Code**: 51111780
**Class**: [Antineoplastic antibiotics](Antineoplastic antibiotics.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[5] It is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

